Skip to main content

Advertisement

Springer Nature Link
Log in

Endocrine Tumors Causing Arterial Hypertension: Pathophysiological Mechanisms and Clinical Implications

  • Review Article
  • Published:
High Blood Pressure & Cardiovascular Prevention Aims and scope Submit manuscript

Abstract

Some tumors are a relatively rare and amendable cause of hypertension, often associated with a higher cardiovascular morbidity and mortality, as compared with that of both general population and patients with essential hypertension. This worse prognosis is not entirely related to blood pressure increase, because the release of substances from the tumor can directly influence blood pressure behavior. Diagnostic approach is challenging and needs a deep knowledge of the different neuro-hormonal and genetic mechanisms determining blood pressure increase. Surgical tumor removal can, but not always, cause blood pressure normalization, depending on how early was tumor detection, since a long-standing history of hypertension is often associated with a much weaker effect on blood pressure. Moreover, target organ damage can be affected by the substances themselves released by the tumors as well as by tumor removal. In this review we consider the phenotype and genetic features of patients with tumor-induced hypertension and focus on their diagnostic work-up.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Explore related subjects

Discover the latest articles and news from researchers in related subjects, suggested using machine learning.

References

  1. Mancia G, Fagard R, Narkiewicz K, Task Force Members, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31(7):1281–357. doi:10.1097/01.hjh.0000431740.32696.cc.

    Article  CAS  PubMed  Google Scholar 

  2. Writing Group Members, Mozaffarian D, Benjamin EJ, Go AS, American Heart Association Statistics Committee; Stroke Statistics Subcommittee, et al. Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation. 2016;133(4):e38–360. doi:10.1161/CIR.0000000000000350 (Erratum in: Circulation. 2016;133(15):e599).

  3. Vega J, Bisognano JD. The prevalence, incidence, prognosis, and associated conditions of resistant hypertension. Semin Nephrol. 2014;34(3):247–56. doi:10.1016/j.semnephrol.2014.04.002.

    Article  PubMed  Google Scholar 

  4. Rossi GP, Bernini G, Caliumi C, PAPY Study Investigators, et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol. 2006;48(11):2293–300.

    Article  CAS  PubMed  Google Scholar 

  5. Thomas RM, Ruel E, Shantavasinkul PC, Corsino L. Endocrine hypertension: an overview on the current etiopathogenesis and management options. World J Hypertens. 2015;5(2):14–27.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, Stowasser M, Young WF Jr. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(5):1889–916. doi:10.1210/jc.2015-4061.

  7. Young WF. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol (Oxf). 2007;66(5):607–18.

    Article  CAS  Google Scholar 

  8. Mulatero P, Stowasser M, Loh KC, et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab. 2004;89(3):1045–50.

    Article  CAS  PubMed  Google Scholar 

  9. Rossi GP, Barisa M, Belfiore A, et al. PAPY study Investigators. The aldosterone-renin ratio based on the plasma renin activity and the direct renin assay for diagnosing aldosterone-producing adenoma. J Hypertens. 2010;28(9):1892–9. doi:10.1097/HJH.0b013e32833d2192.

    Article  CAS  PubMed  Google Scholar 

  10. Goodman LS, Brunton LL, Gilman A, Chabner B, Knollmann BC. Goodman & Gilman’s the pharmacological basis of therapeutics. New York: McGraw-Hill Medical; 2011. p. 692–4.

    Google Scholar 

  11. Rossi GP, Cesari M, Pessina AC. Left ventricular changes in primary aldosteronism. Am J Hypertens. 2003;16(1):96–8.

    Article  PubMed  Google Scholar 

  12. Pimenta E, Gordon RD, Ahmed AH, et al. Cardiac dimensions are largely determined by dietary salt in patients with primary aldosteronism: results of a case-control study. J Clin Endocrinol Metab. 2011;96(9):2813–20. doi:10.1210/jc.2011-0354.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Bernini G, Galetta F, Franzoni F, et al. Arterial stiffness, intima-media thickness and carotid artery fibrosis in patients with primary aldosteronism. J Hypertens. 2008;26(12):2399–405. doi:10.1097/HJH.0b013e32831286fd.

    Article  CAS  PubMed  Google Scholar 

  14. Rossi GP, Bernini G, Desideri G, PAPY Study Participants, et al. Renal damage in primary aldosteronism: results of the PAPY Study. Hypertension. 2006;48(2):232–8.

    Article  CAS  PubMed  Google Scholar 

  15. Schmidt BM, Schmieder RE. Aldosterone-induced cardiac damage: focus on blood pressure independent effects. Am J Hypertens. 2003;16(1):80–6.

    Article  CAS  PubMed  Google Scholar 

  16. Mulatero P, Monticone S, Bertello C, et al. Longterm cardio- and cerebrovascular events in patients with primary aldosteronism. J Clin Endocrinol Metab. 2013;98:4826–33.

    Article  CAS  PubMed  Google Scholar 

  17. Fallo F, Veglio F, Bertello C, et al. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrinol Metab. 2006;91(2):454–9.

    Article  CAS  PubMed  Google Scholar 

  18. Petramala L, Pignatelli P, Carnevale R, et al. Oxidative stress in patients affected by primary aldosteronism. J Hypertens. 2014;32(10):2022–9. doi:10.1097/HJH.0000000000000284 (discussion 2029).

  19. Rossi GP, Cesari M, Cuspidi C, et al. Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism. Hypertension. 2013;62(1):62–9. doi:10.1161/HYPERTENSIONAHA.113.01316 (Erratum in: Hypertension. 2014;64(6):e7).

  20. Sawka AM, Young WF, Thompson GB, et al. Primary aldosteronism: factors associated with normalization of blood pressure after surgery. Ann Intern Med. 2001;135(4):258–61.

    Article  CAS  PubMed  Google Scholar 

  21. Lumachi F, Ermani M, Basso SM, et al. Long-term results of adrenalectomy in patients with aldosterone-producing adenomas: multivariate analysis of factors affecting unresolved hypertension and review of the literature. Am Surg. 2005;71(10):864–9.

    PubMed  Google Scholar 

  22. Montori VM, Schwartz GL, Chapman AB, et al. Validity of the aldosterone-renin ratio used to screen for primary aldosteronism. Mayo Clin Proc. 2001;76(9):877–82.

    Article  CAS  PubMed  Google Scholar 

  23. Ahmed AH, Gordon RD, Taylor PJ, et al. Effect of contraceptives on aldosterone/renin ratio may vary according to the components of contraceptive, renin assay method, and possibly route of administration. J Clin Endocrinol Metab. 2011;96(6):1797–804. doi:10.1210/jc.2010-2918.

    Article  CAS  PubMed  Google Scholar 

  24. Weinberger MH, Fineberg NS. The diagnosis of primary aldosteronism and separation of two major subtypes. Arch Intern Med. 1993;153(18):2125–9.

    Article  CAS  PubMed  Google Scholar 

  25. Ducher M, Mounier-Véhier C, Baguet JP, et al. Aldosterone-to-renin ratio for diagnosing aldosterone-producing adenoma: a multicentre study. Arch Cardiovasc Dis. 2012;105(12):623–30. doi:10.1016/j.acvd.2012.07.006.

    Article  PubMed  Google Scholar 

  26. Bystrom CE, Salameh W, Reitz R, Clarke NJ. Plasma renin activity by LC-MS/MS: development of a prototypical clinical assay reveals a subpopulation of human plasma samples with substantial peptidase activity. Clin Chem. 2010;56(10):1561–9. doi:10.1373/clinchem.2010.146449.

    Article  CAS  PubMed  Google Scholar 

  27. Young WF, Stanson AW, Thompson GB, et al. Role for adrenal venous sampling in primary aldosteronism. Surgery. 2004;136(6):1227–35.

    Article  PubMed  Google Scholar 

  28. Kempers MJ, Lenders JW, van Outheusden L, et al. Systematic review: diagnostic procedures to differentiate unilateral from bilateral adrenal abnormality in primary aldosteronism. Ann Intern Med. 2009;151(5):329–37.

    Article  PubMed  Google Scholar 

  29. Monticone S, Viola A, Rossato D, et al. Adrenal vein sampling in primary aldosteronism: towards a standardised protocol. Lancet Diabetes Endocrinol. 2015;3(4):296–303. doi:10.1016/S2213-8587(14)70069-5.

    Article  CAS  PubMed  Google Scholar 

  30. Rossi GP, Auchus RJ, Brown M, et al. An expert consensus statement on use of adrenal vein sampling for the subtyping of primary aldosteronism. Hypertension. 2014;63(1):151–60. doi:10.1161/HYPERTENSIONAHA.113.02097.

    Article  CAS  PubMed  Google Scholar 

  31. Rossi GP, Barisa M, Allolio B, et al. The Adrenal Vein Sampling International Study (AVIS) for identifying the major subtypes of primary aldosteronism. J Clin Endocrinol Metab. 2012;97(5):1606–14. doi:10.1210/jc.2011-2830.

    Article  CAS  PubMed  Google Scholar 

  32. Crudo V, Monticone S, Burrello J, et al. Hyperaldosteronism: how to discriminate among different disease forms? High Blood Press Cardiovasc Prev. 2016;23(3):203–8. doi:10.1007/s40292-016-0151-6.

    Article  CAS  PubMed  Google Scholar 

  33. Funder JW. Genetic disorders in primary aldosteronism-familial and somatic. J Steroid Biochem Mol Biol. 2017;165(Pt A):154–157. doi:10.1016/j.jsbmb.2016.03.020.

  34. Lenzini L, Rossi GP. The molecular basis of primary aldosteronism: from chimeric gene to channelopathy. Curr Opin Pharmacol. 2015;21:35–42. doi:10.1016/j.coph.2014.12.005.

    Article  CAS  PubMed  Google Scholar 

  35. Lenzini L, Rossitto G, Maiolino G, et al. A meta-analysis of somatic KCNJ5 K(+) channel mutations in 1636 patients with an aldosterone-producing adenoma. J Clin Endocrinol Metab. 2015;100(8):E1089–95. doi:10.1210/jc.2015-2149.

    Article  PubMed  Google Scholar 

  36. Pivonello R, De Martino MC, De Leo M, Lombardi G, Colao A. Cushing’s syndrome. Endocrinol Metab Clin N Am. 2008;37(1):135–49, ix. doi:10.1016/j.ecl.2007.10.010.

  37. Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2008;93(5):1526–40. doi:10.1210/jc.2008-0125.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Valassi E, Santos A, Yaneva M, ERCUSYN Study Group, et al. The European Registry on Cushing’s syndrome: 2-year experience. Baseline demographic and clinical characteristics. Eur J Endocrinol. 2011;165(3):383–92. doi:10.1530/EJE-11-0272.

    Article  CAS  PubMed  Google Scholar 

  39. Isidori AM, Graziadio C, Paragliola RM, ABC Study Group, et al. The hypertension of Cushing’s syndrome: controversies in the pathophysiology and focus on cardiovascular complications. J Hypertens. 2015;33(1):44–60. doi:10.1097/HJH.0000000000000415.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Ceccato F, Barbot M, Zilio M, et al. Screening tests for Cushing’s syndrome: urinary free cortisol role measured by LC–MS/MS. J Clin Endocrinol Metab. 2015;100(10):3856–61. doi:10.1210/jc.2015-2507.

    Article  CAS  PubMed  Google Scholar 

  41. Ceccato F, Boscaro M. Cushing’s syndrome: screening and diagnosis. High Blood Press Cardiovasc Prev. 2016;23(3):209–15. doi:10.1007/s40292-016-0153-4.

    Article  CAS  PubMed  Google Scholar 

  42. Graversen D, Vestergaard P, Stochholm K, Gravholt CH, Jørgensen JO. Mortality in Cushing’s syndrome: a systematic review and meta-analysis. Eur J Intern Med. 2012;23(3):278–82. doi:10.1016/j.ejim.2011.10.013.

    Article  CAS  PubMed  Google Scholar 

  43. Toja PM, Branzi G, Ciambellotti F, et al. Clinical relevance of cardiac structure and function abnormalities in patients with Cushing’s syndrome before and after cure. Clin Endocrinol (Oxf). 2012;76(3):332–8. doi:10.1111/j.1365-2265.2011.04206.x.

    Article  CAS  Google Scholar 

  44. Frustaci A, Letizia C, Verardo R, et al. Cushing syndrome cardiomyopathy: clinicopathologic impact of cortisol normalization. Circ Cardiovasc Imaging. 2016;9(4):e004569. doi:10.1161/CIRCIMAGING.116.004569.

    Article  PubMed  Google Scholar 

  45. Frustaci A, Letizia C, Verardo R, et al. Atrogin-1 pathway activation in cushing syndrome cardiomyopathy. J Am Coll Cardiol. 2016;67(1):116–7. doi:10.1016/j.jacc.2015.10.040.

    Article  PubMed  Google Scholar 

  46. Nieman LK, Biller BM, Findling JW, Endocrine Society, et al. Treatment of Cushing’s syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(8):2807–31. doi:10.1210/jc.2015-1818.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Petramala L, Cavallaro G, Galassi M, et al. Clinical benefits of unilateral adrenalectomy in patients with subclinical hypercortisolism due to adrenal incidentaloma: results from a single center. High Blood Press Cardiovasc Prev. 2017;24(1):69–75. doi:10.1007/s40292-017-0182-7.

    Article  PubMed  Google Scholar 

  48. Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma. Lancet. 2005;366(9486):665–75.

  49. Zuber SM, Kantorovich V, Pacak K. Hypertension in pheochromocytoma: characteristics and treatment. Endocrinol Metab Clin N Am. 2011;40(2):295–311, vii. doi:10.1016/j.ecl.2011.02.002.

  50. Bravo EL, Tagle R. Pheochromocytoma: state-of-the-art and future prospects. Endocr Rev. 2003;24(4):539–53.

    Article  CAS  PubMed  Google Scholar 

  51. Zelinka T, Strauch B, Pecen L, Widimský J Jr. Diurnal blood pressure variation in pheochromocytoma, primary aldosteronism and Cushing’s syndrome. J Hum Hypertens. 2004;18(2):107–11.

    Article  CAS  PubMed  Google Scholar 

  52. Eisenhofer G, Rivers G, Rosas AL, et al. Adverse drug reactions in patients with phaeochromocytoma: incidence, prevention and management. Drug Saf. 2007;30(11):1031–62.

    Article  CAS  PubMed  Google Scholar 

  53. Stolk RF, Bakx C, Mulder J, et al. Is the excess cardiovascular morbidity in pheochromocytoma related to blood pressure or to catecholamines? J Clin Endocrinol Metab. 2013;98(3):1100–6. doi:10.1210/jc.2012-3669.

  54. Lenders JW, Duh QY, Eisenhofer G, Endocrine Society, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(6):1915–42. doi:10.1210/jc.2014-1498.

    Article  CAS  PubMed  Google Scholar 

  55. Oliva R, Angelos P, Kaplan E, Bakris G. Pheochromocytoma in pregnancy: a case series and review. Hypertension. 2010;55(3):600–6. doi:10.1161/HYPERTENSIONAHA.109.147579.

    Article  CAS  PubMed  Google Scholar 

  56. Lenders JW, Pacak K, Walther MM, et al. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA. 2002;287(11):1427–34.

    Article  CAS  PubMed  Google Scholar 

  57. Sawka AM, Prebtani AP, Thabane L, et al. A systematic review of the literature examining the diagnostic efficacy of measurement of fractionated plasma free metanephrines in the biochemical diagnosis of pheochromocytoma. BMC Endocr Disord. 2004;4(1):2.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Taylor RL, Singh RJ. Validation of liquid chromatography-tandem mass spectrometry method for analysis of urinary conjugated metanephrine and normetanephrine for screening of pheochromocytoma. Clin Chem. 2002;48(3):533–9.

    CAS  PubMed  Google Scholar 

  59. Costa MH, Ortiga-Carvalho TM, Violante AD, Vaisman M. Pheochromocytomas and paragangliomas: clinical and genetic approaches. Front Endocrinol (Lausanne). 2015;17(6):126. doi:10.3389/fendo.2015.00126.

    Google Scholar 

  60. Neumann HP, Bausch B, McWhinney SR, Freiburg-Warsaw-Columbus Pheochromocytoma Study Group, et al. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med. 2002;346(19):1459–66.

    Article  CAS  PubMed  Google Scholar 

  61. Welander J, Söderkvist P, Gimm O. Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas. Endocr Relat Cancer. 2011;18(6):R253–76. doi:10.1530/ERC-11-0170.

    Article  CAS  PubMed  Google Scholar 

  62. Baysal BE, Ferrell RE, Willett-Brozick JE, et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science. 2000;287(5454):848–51.

    Article  CAS  PubMed  Google Scholar 

  63. Eisenhofer G, Walther MM, Huynh TT, et al. Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes. J Clin Endocrinol Metab. 2001;86(5):1999–2008.

    Article  CAS  PubMed  Google Scholar 

  64. Rossi GP, Ceolotto G, Caroccia B, Lenzini L. Genetic screening in arterial hypertension. Nat Rev Endocrinol. 2017. doi:10.1038/nrendo.2016.196 (Epub ahead of print).

  65. Janssen I, Chen CC, Millo CM, et al. PET/CT comparing (68)Ga-DOTATATE and other radiopharmaceuticals and in comparison with CT/MRI for the localization of sporadic metastatic pheochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2016;43(10):1784–91. doi:10.1007/s00259-016-3357-x.

    Article  CAS  PubMed  Google Scholar 

  66. Timmers HJ, Chen CC, Carrasquillo JA, et al. Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J Clin Endocrinol Metab. 2009;94(12):4757–67. doi:10.1210/jc.2009-1248.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Klimstra DS, Modlin IR, Coppola D, et al. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas. 2010;39(6):707–12. doi:10.1097/MPA.0b013e3181ec124e.

    Article  PubMed  Google Scholar 

  68. O’Toole D, Grossman A, Gross D, Mallorca Consensus Conference participants.; European Neuroendocrine Tumor Society, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biochemical markers. Neuroendocrinology. 2009;90(2):194–202. doi:10.1159/000225948.

    Article  PubMed  Google Scholar 

  69. Gabriel M, Decristoforo C, Kendler D, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007;48(4):508–18.

    Article  CAS  PubMed  Google Scholar 

  70. O’Toole D, Ducreux M, Bommelaer G, et al. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer. 2000;88(4):770–6.

    Article  PubMed  Google Scholar 

  71. Kulke MH, Hörsch D, Caplin ME, et al. Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome. J Clin Oncol. 2017;35(1):14–23.

    Article  PubMed  Google Scholar 

  72. Melmed S. Medical progress: acromegaly. N Engl J Med. 2006;355(24):2558–73 (Erratum in: N Engl J Med. 2007;356(8):879).

  73. López-Velasco R, Escobar-Morreale HF, Vega B, et al. Cardiac involvement in acromegaly: specific myocardiopathy or consequence of systemic hypertension? J Clin Endocrinol Metab. 1997;82(4):1047–53.

    PubMed  Google Scholar 

  74. Melmed S, Colao A, Barkan A, Acromegaly Consensus Group, et al. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab. 2009;94(5):1509–17. doi:10.1210/jc.2008-2421.

    Article  CAS  PubMed  Google Scholar 

  75. Wong L, Hsu TH, Perlroth MG, et al. Reninoma: case report and literature review. J Hypertens. 2008;26(2):368–73. doi:10.1097/HJH.0b013e3282f283f3.

    Article  CAS  PubMed  Google Scholar 

  76. Wolley M, Gordon RD, Stowasser M. Reninoma: the importance of renal vein renin ratios for lateralisation and diagnosis. Am J Nephrol. 2014;39(1):16–9. doi:10.1159/000357410.

    Article  CAS  PubMed  Google Scholar 

  77. Vidal-Petiot E, Bens M, Choudat L, et al. A case report of reninoma: radiological and pathological features of the tumour and characterization of tumour-derived juxtaglomerular cells in culture. J Hypertens. 2015;33(8):1709–15. doi:10.1097/HJH.0000000000000592.

    Article  CAS  PubMed  Google Scholar 

  78. Agabiti Rosei C, Giacomelli L, Salvetti M, et al. Advantages of renin inhibition in a patient with reninoma. Int J Cardiol. 2015;187:240–2. doi:10.1016/j.ijcard.2015.03.280.

    Article  Google Scholar 

  79. Schiffl H, Lang SM. Hypertension secondary to PHPT: cause or coincidence? Int J Endocrinol. 2011;2011:974647. doi:10.1155/2011/974647.

    Article  PubMed  PubMed Central  Google Scholar 

  80. Khan AA, Hanley DA, Rizzoli R, et al. Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus. Osteoporos Int. 2017;28(1):1–19. doi:10.1007/s00198-016-3716-2.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. From the Academic Unit of Internal Medicine and Hypertension Centre, Department of Clinical and Experimental Medicine, University of Catania, c/o Cannizzaro Hospital, Via Messina 829, 95126, Catania, Italy

    Agata Buonacera, Benedetta Stancanelli & Lorenzo Malatino

Authors
  1. Agata Buonacera
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. Benedetta Stancanelli
    View author publications

    You can also search for this author inPubMed Google Scholar

  3. Lorenzo Malatino
    View author publications

    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence to Lorenzo Malatino.

Ethics declarations

Conflict of interest

The Authors declare that they have no conflict of interest.

Informed consent

For this type of study formal consent is not required.

Research involving human participants or animals

This article is a Review and does not contain any study with human participants or animals.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Buonacera, A., Stancanelli, B. & Malatino, L. Endocrine Tumors Causing Arterial Hypertension: Pathophysiological Mechanisms and Clinical Implications. High Blood Press Cardiovasc Prev 24, 217–229 (2017). https://doi.org/10.1007/s40292-017-0200-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40292-017-0200-9

Keywords